BradleyLawrenceFreilichMDFAASLD,AGAF, CCI
Gastroenterology • Kansas City, MOAdvanced Endoscopic Interventional, Hepatology & Liver Transplantation, Inflammatory Bowel Disease, Bariatric Medicine
Partner Kansas City Gastroenterology Director Liver and Pancreas Institute of Kansas City Director Kansas City Research Institute Director HCA Metabolic Syndrome/Weight Loss Center
Dr. Freilich is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6675 Holmes Rd Ste 430
Kansas City, MO 64131Phone+1 816-361-0055Fax+1 816-552-5899
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 1991 - 1994
Rush University Medical CenterResidency, Internal Medicine, 1988 - 1991
University of Missouri Kansas City School of MedicineClass of 1988
Certifications & Licensure
CA State Medical License 1991 - Present
KS State Medical License 1994 - 2025
MO State Medical License 1994 - 2025- American Board of Internal Medicine Gastroenterology
- American Board of Obesity Medicine Obesity Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Fellow (AGAF) American Gastroenterological Association, 2006
Clinical Trials
- Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Start of enrollment: 2014 Mar 27
- Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Start of enrollment: 2014 Apr 01
- Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing Start of enrollment: 2014 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.Mary E Rinella, Hsiao D Lieu, Kris V Kowdley, Zachary D Goodman, Naim Alkhouri
Hepatology. 2024-03-01 - 32 citationsA randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.Stephen A Harrison, Peter J Ruane, Bradley Freilich, Guy Neff, Rashmee Patil
JHEP Reports. 2023-01-01 - 44 citationsAldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy
The Lancet. Gastroenterology & Hepatology. 2022-07-01
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
